Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk

Rhea-AI Summary

Relief Therapeutics Holding SA reported on July 4, 2022, that the FDA has declined to issue an Emergency Use Authorization (EUA) for aviptadil concerning a subgroup of patients also receiving remdesivir. This decision impacts the company as it collaborates with NRx Pharmaceuticals, whose subsidiary, NeuroRx, is involved with aviptadil's development. Relief is involved in clinical-stage programs aimed at serious unmet medical needs, including various metabolic disorders. The firm has also expanded its pipeline through recent acquisitions.

Positive

• Collaboration with Acer Therapeutics for the development of ACER-001.
• Recent acquisitions that diversify the product pipeline.

Negative

• FDA's decline for aviptadil EUA may hinder future revenue potential.
• Dependency on NeuroRx's outcomes could present risks.

GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (" NRx "), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. (" NeuroRx "), has announced that the U.S. Food and Drug Administration (" FDA ") has declined to issue an Emergency Use Authorization (EUA) for aviptadil for a subgroup of patients that, in addition to aviptadil, also received remdesivir and continued to progress. The related NRx press release can be accessed through the following link .

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Relief also continues to study aviptadil for several possible lung related conditions. Finally, Relief's 2021 acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH brought to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com . Follow us on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether RELIEF THERAPEUTICS Holding SA will be successful in its lawsuit against NRx's subsidiary, NeuroRx, and NeuroRx's CEO, Jonathan Javitt, and in defending NeuroRx's lawsuit against Relief, (ii) whether aviptadil will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with COVID-19 or any other disease, and (iii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX and with the U.S. Securities and Exchange Commission, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com:
https://www.accesswire.com/707458/Relief-Reports-that-its-US-Collaboration-Partner-has-Announced-that-the-FDA-has-Declined-Emergency-Use-Authorization-for-Aviptadil-for-a-Subgroup-of-Patients-with-Critical-COVID-19-at-Immediate-Risk

FAQ

What was the FDA's decision regarding aviptadil from Relief Therapeutics?

The FDA declined to issue an Emergency Use Authorization for aviptadil for a subgroup of patients.

How does the FDA's decision affect Relief Therapeutics' stock?

The decision may hinder future revenue potential and investor confidence in the stock RLFTY, RLFTF.

What collaborations does Relief Therapeutics have?

Relief has a collaboration agreement with Acer Therapeutics for ACER-001 and partners with NRx Pharmaceuticals for aviptadil.

What are the recent acquisitions by Relief Therapeutics?

Relief recently acquired APR Applied Pharma Research SA and AdVita Lifescience GmbH, enhancing its product pipeline.